Results 121 to 130 of about 19,015 (246)

The long-term cost-effectiveness of once-weekly semaglutide versus sitagliptin for the treatment of type 2 diabetes in China

Health Economics Review
Background To estimate the long-term cost-effectiveness of once-weekly semaglutide versus sitagliptin as an add-on therapy for type 2 diabetes patients inadequately controlled on metformin in China, to better inform healthcare decision making.
Shuyan Gu, Jinghong Gu, Xiaoyong Wang, Xiaoling Wang, Lu Li, Hai Gu, Biao Xu   +6 more
doaj   +1 more source

Proteomic changes upon treatment with semaglutide in individuals with obesity [PDF]

Obesity and type 2 diabetes are prevalent chronic diseases effectively managed by semaglutide. Here we studied the effects of semaglutide on the circulating proteome using baseline and end-of-treatment serum samples from two phase 3 trials in ...
Galanakis, Michael, Geybels, Milan, Gill, Dipender, Iglesias, Miquel Triana, Knudsen, Lotte Bjerre, Maretty, Lasse, Purnell, Jonathan Q, Secher, Anna, Sibbesen, Jonas, Simonsen, Lotte, Soh, Keng, Tahrani, Abd, Valkenborg, Dirk, Zagkos, Loukas   +13 more
core   +1 more source

Development of NAFLD‐Specific Human Liver Organoid Models on a Microengineered Array Chip for Semaglutide Efficacy Evaluation

Cell Proliferation, EarlyView.
Microporous array organ chips were integrated with commercially available well plates to develop organoid chip platforms, which enable modelling of hepatic physiology and non‐alcoholic fatty liver disease (NAFLD) pathogenesis, as well as evaluation of semaglutide therapeutics. ABSTRACT Progressive non‐alcoholic fatty liver disease (NAFLD) may culminate
Xiao‐yan You, Xiang‐yang Li, Hui Wang, Guo‐ping Zhao   +3 more
wiley   +1 more source

Eloralintide, a selective, long‐acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aim Eloralintide (LY3841136) is a potent, long‐acting selective amylin receptor agonist currently under development for the treatment of obesity with once‐weekly subcutaneous dosing. Materials and Methods This 12‐week Phase 1, randomised, placebo‐controlled, participant‐ and investigator‐blinded, multiple ascending dose study evaluated the ...
Shobha Bhattachar, Lai San Tham, Beth Tidemann‐Miller, Hilda Ibriga, Hongchang Qu, Daniel A. Briere, Axel Haupt, Kieren J. Mather, Edward Pratt   +8 more
wiley   +1 more source

Long-term Effect of Oral Semaglutide on Glycemic Control: An Extended Observational Study over Two Years from Baseline [PDF]

The aim of this study is to investigate the long-term effect of oral semaglutide on glycemic control. The effect on glycemic control of switching from a DPP4 inhibitor to oral semaglutide was examined in an extended period of 2 years from baseline in ...
Hara, Kenji, Hashimoto, Koshi, Takebayashi, Kohzo, Tsuchiya, Takafumi, Yamauchi, Mototaka   +4 more
core   +1 more source

Comparison of cardiovascular outcomes between once‐weekly semaglutide and dulaglutide in adults with type 2 diabetes and established atherosclerotic cardiovascular disease in the United States

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims This study aims to compare the risk of major adverse cardiovascular events (MACE) among United States individuals with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD) treated with once‐weekly semaglutide vs. dulaglutide.
Xi Tan, Yuanjie Liang, Lin Xie, Joanna Harton, Cynthia Gutierrez, Chalak Muhammad, Caroline Swift, Adam de Havenon   +7 more
wiley   +1 more source

The GLP-1 medicines semaglutide and tirzepatide do not alter disease-related pathology, behaviour or cognitive function in 5XFAD and APP/PS1 mice

Molecular Metabolism
Objective: The development of glucagon-like peptide-1 receptor (GLP-1R) agonists for the treatment of type 2 diabetes and obesity has been accompanied by evidence for anti-inflammatory and cytoprotective actions in the heart, blood vessels, kidney, and ...
Leticia Forny Germano, Jacqueline A. Koehler, Laurie L. Baggio, Fiona Cui, Chi Kin Wong, Nikolaj Rittig, Xiemin Cao, Dianne Matthews, Daniel J. Drucker   +8 more
doaj   +1 more source

Semaglutide vs Liraglutide for Weight Loss in Adults with Obesity [PDF]

Introduction: Obesity is a growing chronic condition worldwide with limited effective and safe treatment options. Semaglutide and liraglutide are two GLP-1a medications with encouraging outcomes for the treatment of obesity.
Bar, Orian
core   +1 more source

GLP‐1 receptor agonists and cardiovascular outcomes in Asian, Black or African American, and White populations: An updated meta‐analysis including the SOUL trial

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To evaluate the cardiovascular efficacy of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) in Asian, Black or African American, and White populations, and to assess whether the magnitude of cardiovascular risk reduction differs across these populations.
Masashi Hasebe, Chen‐Yang Su, Hisashi Kamido, Daisuke Yabe, Satoshi Yoshiji   +4 more
wiley   +1 more source

The relative risk of clinically relevant cholelithiasis among glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus, real-world study

Diabetology & Metabolic Syndrome
Background and Aim The association between biliary disorders with weight reduction enhanced by GLP-1RAs was observed frequently, nevertheless, the relative risk of the clinically relevant cholelithiasis was not specified clearly among different GLP-1RAs.
Mohammed Ali Gameil, Elshahat Ali Ahmed Mohamed Yousef, Rehab Elsayed Marzouk, Mohamed H. Emara, Abeer H. Abdelkader, Rasha Ibrahim Salama   +5 more
doaj   +1 more source